• 1. Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, P. R. China;
  • 2. Guangxi Key Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer, Nanning 530021, P. R. China;
  • 3. Day Surgery Center, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, P. R. China;
  • 4. Medical Insurance Management Office, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, P. R. China;
PENG Tao, Email: pengtaogmu@163.com
Export PDF Favorites Scan Get Citation

Objective To explore the feasibility of laparoscopic hepatectomy of malignant liver tumors under the day surgery management model based on the concept of enhanced recovery after surgery (ERAS). Methods Three patients who underwent same-day laparoscopic resection of malignant liver tumors in the Department of Hepatobiliary Surgery of the First Affiliated Hospital of Guangxi Medical University from June to November 2022 were retrospectively collected. The clinical application effects of this model were comprehensively evaluated. Results All 3 patients (cases 1–3) successfully completed complete laparoscopic anatomical partial liver resection, with operation times of 155, 183, and 201 min, respectively, and intraoperative blood loss of all <100 mL (20, 100, and 50 mL, respectively). Postoperative pathology confirmed that cases 1 and 2 were hepatocellular carcinoma, and case 3 was colorectal adenocarcinoma with liver metastasis, and the resection margins all met the R0 standard. All patients resumed oral feeding 6 h after surgery and were able to get out of bed within 8 h after surgery. All 3 patients were discharged within 24 h after surgery. The hospitalization cost of the three patients was (22 602.0±3 400.0) yuan. All patients were followed up for more than 24 months and maintained a tumor-free survival state, without tumor recurrence and metastasis. Conclusion The results of this limited cases suggest that same-day laparoscopic liver resection is initially feasible and safe for strictly selected patients with liver malignancies combined with a standardized ERAS management pathway.

Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved